Retension Pharmaceuticals (RTSN) Registration filing summary

Company overview and business model

• Exhibit index lists sublicense agreements covering KD-026 and KD-027, including a 2023 sublicense for KD-027.

Management team and governance

• Eric Keller signed as CEO and director; Alex Schwartz as principal financial and accounting officer; Michael Joseph Berendt as board chair; Franklin M. Berger and Donald Olds as directors.

• The exhibit index includes a consent from Pavan Cheruvu as a prospective director, dated September 18, 2026.

Offering details and pricing

• Amendment No. 2 to the Form S-1 was filed October 7, 2026, solely to submit a revised filing fee table; the remainder of the registration statement was unchanged.

• Proposed public sale was to begin as soon as practicable after the registration statement became effective; the filing sought to delay effectiveness pending a further amendment or SEC determination.

• The exhibit list includes a form of underwriting agreement.